CSL Wins U.S. Government Contract for Flu Vaccines
- By BSTQ Staff
CSL Biotherapies, a subsidiary of CSL Limited, has won a supply contract for pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile from the U.S. Department of Health and Human Services. The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract. Under the terms of the contract, the government may request CSL to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential, to develop working virus seeds for other manufacturers and to formulate, fill and finish bulk stored antigen.
